PTGX Protagonist Therapeutics Inc.

11.71
+0.32  (+3%)
Previous Close 11.4
Open 11.49
Price To Book 3.65
Market Cap 307,871,207
Shares 26,280,086
Volume 108,236
Short Ratio
Av. Daily Volume 213,692
Stock charts supplied by TradingView

NewsSee all news

  1. Protagonist Therapeutics Announces Acceptance of Abstracts at the UEG Week 2019 Meeting and the ACG 2019 Annual Scientific Meeting

    NEWARK, Calif., Oct. 1, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that abstracts providing data from the PN-943 and PTG-200 clinical programs have been accepted for poster

  2. Protagonist Therapeutics Reports Granting of Inducement Awards

    NEWARK, Calif., Sept. 4, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on August 30, 2019, it issued inducement awards to two recently hired employees in accordance with their

  3. Protagonist Therapeutics to Present at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference

    NEWARK, Calif., Sept. 3, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the H.C.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b trial discontinued following interim analysis - March 26, 2018. However, company noted August 6, 2018 that human error by CRO contributed to this decision.
PTG-100
Ulcerative colitis
Phase 2 initial data due 4Q 2019 with final top-line data due 1H 2020.
PTG-300
Beta-thalassemia
Phase 1 data to be presented October 22, 2019 at UEG Week and October 28, 2019, from 10:30 a.m at ACG meeting.
PTG-200
Crohn's disease
Phase 1 data to be presented October 28, 2019, from 10:30 a.m at ACG meeting.
PN-943
Ulcerative colitis
Phase 2 trial to commence early 2020.
PTG-300
Hereditary hemochromatosis
Phase 2 trial to commence 3Q 2019.
PTG-300
Polycythemia vera

Latest News

  1. Protagonist Therapeutics Announces Acceptance of Abstracts at the UEG Week 2019 Meeting and the ACG 2019 Annual Scientific Meeting

    NEWARK, Calif., Oct. 1, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that abstracts providing data from the PN-943 and PTG-200 clinical programs have been accepted for poster

  2. Protagonist Therapeutics Reports Granting of Inducement Awards

    NEWARK, Calif., Sept. 4, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on August 30, 2019, it issued inducement awards to two recently hired employees in accordance with their

  3. Protagonist Therapeutics to Present at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference

    NEWARK, Calif., Sept. 3, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the H.C.